NCT04323189View on ClinicalTrials.gov

Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 26, 2020

Primary Completion Date

December 2, 2024

Study Completion Date

February 28, 2026

Conditions
Genetics DiseaseType2 DiabetesHeart Failure
Interventions
DRUG

Sitagliptin 100mg

Sitagliptin will be administered daily for 7 days, with a study day on day 7.

DRUG

Placebo Oral Tablet

Placebo will be administered daily for 7 days, with a study day on day 7.

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER